Abstract 1606P
Background
Sarcopenia refers to the loss of muscle mass and strength that occurs with aging and due to some medical conditions like cancer. Depression and inability to eat without assistance are common effects documented in cancer patients with sarcopenia. As a result, the goal of this study was to look into the relationship between sarcopenia, depression, and modes of feeding.
Methods
During the period beginning in January 2023 and ending in April 2023, cancer patients participated in a retrospective study. There has been a total of 150 participants enrolled in the trial, all of whom have been diagnosed with cancer. These people were enrolled in Mayo Hospital's Palliative Care Cancer Department in order to receive treatment. The Patient Health Questionnaire (PHQ-9) was used to determine the presence of depressive symptoms. The SARC-F was utilized to assess sarcopenia across all five dimensions. A self-report measure was utilized to assess modes of feeding [options include: 1) unable to eat without assistance 2) (self-fed with some difficulty, and 3) self-fed without any problem]. Sarcopenia, major depressive disorder, and feeding modes were studied using correlation analysis.
Results
We have observed a significant and negative association between modes of feeding and depression (r=-0.459, p<0.01), SARC1=Strength (r = -0.326, p<0.01), SARC2=Assistance in walking (r = -0.196, p<0.05), and SARC3=Rise from a chair (r = -0.238, p<0.01). These findings show that cancer patients are unable to eat without assistance when they suffer from sarcopenia which ultimately leads to more depressive symptoms.
Conclusions
Sarcopenia has a negative impact on the quality of life of patients, leading to depression and dependence on daily activities like self-eating which further complicates management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05